1. Volume 87, Issue 1, Pages 210-216 (January 2015)
Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease 
Björn Meijers, Ruben Poesen, Kathleen Claes, Ruth Dietrich, Bert Bammens, Ben Sprangers, Maarten Naesens, Markus Storr, Dirk Kuypers, Pieter Evenepoel 
Kidney International 
Volume 87, Issue 1, Pages (January 2015)
DOI: /ki
Copyright © 2015 International Society of Nephrology Terms and Conditions

2. Figure 1
Patient enrollment during the study period. CKD, chronic kidney disease; FSGS, focal segmental glomerulosclerosis; suPAR, soluble urokinase-type plasminogen activator receptor.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

3. Figure 2
Kaplan–Meier estimate of the fraction of patients with mild-to-moderate chronic kidney disease (CKD) who are alive as a function of tertiles of suPAR concentrations. There is a highly significant (P<0.0001) graded direct relationship between suPAR and the crude mortality risk. suPAR, soluble urokinase-type plasminogen activator receptor. R, reference. *P<0.05.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions

4. Figure 3
Kaplan–Meier estimate of time to first cardiovascular event in patients with mild-to-moderate chronic kidney disease (CKD) as a function of tertiles of soluble urokinase-type plasminogen activator receptor (suPAR) concentrations. R, reference. *P<0.05.
Kidney International  , DOI: ( /ki )
Copyright © 2015 International Society of Nephrology Terms and Conditions